GDF15 mediates the effects of metformin on body weight and energy balance.
Administration, Oral
Adult
Aged
Animals
Blood Glucose
/ analysis
Body Weight
/ drug effects
Diet, High-Fat
Double-Blind Method
Energy Intake
/ drug effects
Energy Metabolism
/ drug effects
Enterocytes
/ cytology
Female
Glial Cell Line-Derived Neurotrophic Factor Receptors
/ antagonists & inhibitors
Growth Differentiation Factor 15
/ blood
Homeostasis
/ drug effects
Humans
Intestines
/ cytology
Male
Metformin
/ administration & dosage
Mice
Mice, Obese
Middle Aged
Weight Loss
/ drug effects
Journal
Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462
Informations de publication
Date de publication:
02 2020
02 2020
Historique:
received:
01
07
2019
accepted:
16
12
2019
pubmed:
26
12
2019
medline:
30
5
2020
entrez:
26
12
2019
Statut:
ppublish
Résumé
Metformin, the world's most prescribed anti-diabetic drug, is also effective in preventing type 2 diabetes in people at high risk
Identifiants
pubmed: 31875646
doi: 10.1038/s41586-019-1911-y
pii: 10.1038/s41586-019-1911-y
pmc: PMC7234839
mid: EMS86333
doi:
Substances chimiques
Blood Glucose
0
GDF15 protein, human
0
GFRAL protein, mouse
0
Gdf15 protein, mouse
0
Glial Cell Line-Derived Neurotrophic Factor Receptors
0
Growth Differentiation Factor 15
0
Metformin
9100L32L2N
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
444-448Subventions
Organisme : Medical Research Council
ID : MC_PC_12009
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 051420
Pays : United Kingdom
Organisme : British Heart Foundation
ID : RG/12/13/29853
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200848
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12015/1
Pays : United Kingdom
Organisme : National Centre for the Replacement, Refinement and Reduction of Animals in Research
ID : NC/T2T0419
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106262
Pays : United Kingdom
Organisme : NCATS NIH HHS
ID : UL1 TR000135
Pays : United States
Organisme : Medical Research Council
ID : G0802051
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12012/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0400192
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12012/5
Pays : United Kingdom
Organisme : Medical Research Council
ID : G0600717
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/2
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_12012/3
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/3
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 107064
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : R21 AG060139
Pays : United States
Organisme : Medical Research Council
ID : MC_UU_12012/2
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 095515
Pays : United Kingdom
Organisme : NIDDK NIH HHS
ID : T32 DK007352
Pays : United States
Organisme : Wellcome Trust
ID : 100574
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/5
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200848/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 106263
Pays : United Kingdom
Organisme : Chief Scientist Office
ID : CZB/4/613
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/1
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 100140
Pays : United Kingdom
Commentaires et corrections
Type : ErratumIn
Références
Knowler, W. C. et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393–403 (2002).
doi: 10.1056/NEJMoa012512
Ramachandran, A. et al. The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49, 289–297 (2006).
doi: 10.1007/s00125-005-0097-z
Lachin, J. M. et al. Factors associated with diabetes onset during metformin versus placebo therapy in the diabetes prevention program. Diabetes 56, 1153–1159 (2007).
doi: 10.2337/db06-0918
Rena, G., Hardie, D. G. & Pearson, E. R. The mechanisms of action of metformin. Diabetologia 60, 1577–1585 (2017).
doi: 10.1007/s00125-017-4342-z
Apolzan, J. W. et al. Long-term weight loss with metformin or lifestyle intervention in the Diabetes Prevention Program Outcomes Study. Ann. Intern. Med. 170, 682–690 (2019).
doi: 10.7326/M18-1605
Gerstein, H. C. et al. Growth differentiation factor 15 as a novel biomarker for metformin. Diabetes Care 40, 280–283 (2017).
doi: 10.2337/dc16-1682
Tsai, V. W. W., Husaini, Y., Sainsbury, A., Brown, D. A. & Breit, S. N. The MIC-1/GDF15–GFRAL pathway in energy homeostasis: implications for obesity, cachexia, and other associated diseases. Cell Metab. 28, 353–368 (2018).
doi: 10.1016/j.cmet.2018.07.018
Mullican, S. E. et al. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat. Med. 23, 1150–1157 (2017).
doi: 10.1038/nm.4392
Emmerson, P. J. et al. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat. Med. 23, 1215–1219 (2017).
doi: 10.1038/nm.4393
Yang, L. et al. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat. Med. 23, 1158–1166 (2017).
doi: 10.1038/nm.4394
Hsu, J. Y. et al. Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. Nature 550, 255–259 (2017).
doi: 10.1038/nature24042
Konopka, A. R. et al. Hyperglucagonemia mitigates the effect of metformin on glucose production in prediabetes. Cell Rep. 15, 1394–1400 (2016).
doi: 10.1016/j.celrep.2016.04.024
Preiss, D. et al. Metformin for non-diabetic patients with coronary heart disease (the CAMERA study): a randomised controlled trial. Lancet Diabetes Endocrinol. 2, 116–124 (2014).
doi: 10.1016/S2213-8587(13)70152-9
McCreight, L. J. et al. Pharmacokinetics of metformin in patients with gastrointestinal intolerance. Diabetes Obes. Metab. 20, 1593–1601 (2018).
doi: 10.1111/dom.13264
Forouhi, N. G., Luan, J., Hennings, S. & Wareham, N. J. Incidence of Type 2 diabetes in England and its association with baseline impaired fasting glucose: the Ely study 1990-2000. Diabet. Med. 24, 200–207 (2007).
doi: 10.1111/j.1464-5491.2007.02068.x
Chung, H. K. et al. Growth differentiation factor 15 is a myomitokine governing systemic energy homeostasis. J. Cell Biol. 216, 149–165 (2017).
doi: 10.1083/jcb.201607110
Li, D., Zhang, H. & Zhong, Y. Hepatic GDF15 is regulated by CHOP of the unfolded protein response and alleviates NAFLD progression in obese mice. Biochem. Biophys. Res. Commun. 498, 388–394 (2018).
doi: 10.1016/j.bbrc.2017.08.096
Patel, S. et al. GDF15 provides an endocrine signal of nutritional stress in mice and humans. Cell Metab. 29, 707–718 (2019).
doi: 10.1016/j.cmet.2018.12.016
Shu, Y. et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422–1431 (2007).
doi: 10.1172/JCI30558
DeFronzo, R. A. et al. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials. Diabetologia 59, 1645–1654 (2016).
doi: 10.1007/s00125-016-3992-6
Preiss, D. et al. Sustained influence of metformin therapy on circulating glucagon-like peptide-1 levels in individuals with and without type 2 diabetes. Diabetes Obes. Metab. 19, 356–363 (2017).
doi: 10.1111/dom.12826
Bahne, E. et al. Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. JCI Insight 3, 93936 (2018).
doi: 10.1172/jci.insight.93936
Maida, A., Lamont, B. J., Cao, X. & Drucker, D. J. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice. Diabetologia 54, 339–349 (2011).
doi: 10.1007/s00125-010-1937-z
de la Cuesta-Zuluaga, J. et al. Metformin is associated with higher relative abundance of mucin-degrading Akkermansia muciniphila and several short-chain fatty acid-producing microbiota in the gut. Diabetes Care 40, 54–62 (2017).
doi: 10.2337/dc16-1324
Shin, N. R. et al. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63, 727–735 (2014).
doi: 10.1136/gutjnl-2012-303839
Forslund, K. et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262–266 (2015).
doi: 10.1038/nature15766
Foretz, M., Guigas, B. & Viollet, B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nat. Rev. Endocrinol. 15, 569–589 (2019).
doi: 10.1038/s41574-019-0242-2
Massollo, M. et al. Metformin temporal and localized effects on gut glucose metabolism assessed using
doi: 10.2967/jnumed.112.106666
Buse, J. B. et al. The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care 39, 198–205 (2016).
doi: 10.2337/dc15-1531
Skarnes, W. C. et al. A conditional knockout resource for the genome-wide study of mouse gene function. Nature 474, 337–342 (2011).
doi: 10.1038/nature10163
Bradley, A. et al. The mammalian gene function resource: the International Knockout Mouse Consortium. Mamm. Genome 23, 580–586 (2012).
doi: 10.1007/s00335-012-9422-2
Pettitt, S. J. et al. Agouti C57BL/6N embryonic stem cells for mouse genetic resources. Nat. Methods 6, 493–495 (2009).
doi: 10.1038/nmeth.1342
McNeilly, A. D., Williamson, R., Balfour, D. J., Stewart, C. A. & Sutherland, C. A high-fat-diet-induced cognitive deficit in rats that is not prevented by improving insulin sensitivity with metformin. Diabetologia 55, 3061–3070 (2012).
doi: 10.1007/s00125-012-2686-y
Ortega-Cava, C. F. et al. Strategic compartmentalization of Toll-like receptor 4 in the mouse gut. J. Immunol. 170, 3977–3985 (2003).
doi: 10.4049/jimmunol.170.8.3977
Goldspink, D. A. et al. Mechanistic insights into the detection of free fatty and bile acids by ileal glucagon-like peptide-1 secreting cells. Mol. Metab. 7, 90–101 (2018).
doi: 10.1016/j.molmet.2017.11.005
Sato, T. et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology 141, 1762–1772 (2011).
doi: 10.1053/j.gastro.2011.07.050
Rashid, S. T. et al. Modeling inherited metabolic disorders of the liver using human induced pluripotent stem cells. J. Clin. Invest. 120, 3127–3136 (2010).
doi: 10.1172/JCI43122
Yusa, K. et al. Targeted gene correction of α1-antitrypsin deficiency in induced pluripotent stem cells. Nature 478, 391–394 (2011).
doi: 10.1038/nature10424
Chen, G. et al. Chemically defined conditions for human iPSC derivation and culture. Nat. Methods 8, 424–429 (2011).
doi: 10.1038/nmeth.1593
Hannan, N. R., Segeritz, C. P., Touboul, T. & Vallier, L. Production of hepatocyte-like cells from human pluripotent stem cells. Nat. Protoc. 8, 430–437 (2013).
doi: 10.1038/nprot.2012.153